Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02729233|
Recruitment Status : Withdrawn (Funding withdrawn)
First Posted : April 6, 2016
Last Update Posted : January 8, 2018
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD). UC is an ongoing disease of the colon or large intestine. Studies have shown that leakiness of the gut plays a major role in the development of UC. Leakiness of the gut is a condition that is a result of damage to the intestinal lining, making it less able to protect its internal environment as well as to filter needed nutrients and other substances. Some bacteria, toxins, and waste not normally absorbed may get into the blood stream.
Golimumab is an FDA approved medication used for the treatment of moderate to severe ulcerative colitis. The investigators have evidence to suggest that measuring the leakiness of the gut using a tool called a confocal laser endomicroscope may be able to predict how well a patient's body will respond to treatment of UC with golimumab. Confocal laser endomicroscopy (CLE) is an FDA approved technique that can look at the cells of a patient's gut during colonoscopy to assess the leakiness of gut.
The objective of this study is to determine how the leakiness of the gut in patients with UC can predict response to golimumab therapy.
|Condition or disease||Intervention/treatment||Phase|
|Ulcerative Colitis||Other: patients receiving biopsies||Not Applicable|
The objective of this pilot study is to determine the predictive value of mucosal barrier dysfunction for a therapeutic response to golimumab in UC patients. This objective is based on the investigator's hypothesis that barrier dysfunction is a potent predictor of response to anti-tumor necrosis factor (TNF) therapy. This hypothesis is based on the following observations: (1) IBD patients with higher gap densities have higher mucosal pro-inflammatory cytokine levels; (2) the highest rates of response to biologic therapy for Ulcerative colitis are seen in post-operative patients, with over 90% endoscopic remission rate at one year; and (3) prominent barrier dysfunction is observed at the anastomotic site in animal models of ileal resection. Therefore, the investigators hypothesize that barrier dysfunction is a potent predictor of therapeutic response to golimumab in UC patients.
In 30 UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based CLE (pCLE). Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
Secondary study endpoints are: (1) The rate of clinical remission at 3 months following initiation of golimumab. (2) The rate of clinical remission at 12 months following initiation of golimumab. (3) Endoscopic and histological evidence of mucosal healing at one-year follow-up colonoscopy.
Clinical Response & Remission definitions are: (1) Clinical Remission: partial Mayo score of 2 points, without any sub-score >1. (2) Clinical Response: reduction of partial Mayo UC score by ≥ 30% and ≥ 2 points, with a rectal bleeding sub-score of ≤ 1 or a decrease in the bleeding sub-score of ≥ 1.
Endoscopic and histologic mucosal healing definitions: (1) Endoscopic: Mayo endoscopic score of 0 or 1. (2) Histologic: Riley's histological score ≤ 6.
The investigators proposal is based on clinical, translational and basic evidence of barrier dysfunction in the pathogenesis of UC. With the development of a robust prediction model for therapeutic response, UC patients can be treated more effectively with golimumab. Using a stratified approach, higher therapeutic response rate may eventually yield a new "intelligent step-up" treatment strategy in this personalized medicine era.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction|
|Study Start Date :||January 2017|
|Actual Primary Completion Date :||January 27, 2017|
|Actual Study Completion Date :||January 27, 2017|
patients receiving biopsies
UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE).
Other: patients receiving biopsies
Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
- Rate of improvement in mucosal barrier function as measured by pCLE [ Time Frame: up to 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02729233
|Principal Investigator:||Julia J Liu, MD||University of Arkansas|